US 11,718,668 B2
Checkpoint blockade and microsatellite instability
Luis Diaz, Ellicot City, MD (US); Bert Vogelstein, Baltimore, MD (US); Kenneth W. Kinzler, Baltimore, MD (US); Nickolas Papadopoulos, Towson, MD (US); Dung Le, Lutherville, MD (US); Drew M. Pardoll, Brookville, MD (US); and Suzanne L. Topalian, Brookville, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on May 9, 2022, as Appl. No. 17/739,274.
Application 17/739,274 is a continuation of application No. 17/131,339, filed on Dec. 22, 2020, granted, now 11,325,975.
Application 17/131,339 is a continuation of application No. 16/144,549, filed on Sep. 27, 2018, granted, now 10,934,356, issued on Mar. 2, 2021.
Application 16/144,549 is a continuation of application No. 15/523,451, abandoned, previously published as PCT/US2015/060331, filed on Nov. 12, 2015.
Claims priority of provisional application 62/190,977, filed on Jul. 10, 2015.
Claims priority of provisional application 62/079,357, filed on Nov. 13, 2014.
Prior Publication US 2022/0275086 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 31/00 (2006.01); G01N 33/53 (2006.01); C07K 16/28 (2006.01); C12Q 1/6886 (2018.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); C07K 16/40 (2013.01); C12Q 1/6886 (2013.01); C12Y 113/11052 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55 (2013.01); C07K 2317/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)] 30 Claims
 
1. A method of treating colorectal cancer in a human patient, the method comprising
testing or having tested a biological sample obtained from a patient having colorectal cancer, thereby determining that the patient's colorectal cancer is microsatellite instability high or DNA mismatch repair deficient; and
in response to determining that the colorectal cancer is microsatellite instability high or DNA mismatch repair deficient, treating the patient determined to have microsatellite instability high or DNA mismatch repair deficient colorectal cancer with a therapeutically effective amount of an anti-PD-1 antibody.